|
1
|
ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.
|
Mol Cell Biol
|
2004
|
2.46
|
|
2
|
Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex.
|
Proc Natl Acad Sci U S A
|
2003
|
1.99
|
|
3
|
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.
|
Cancer Res
|
2010
|
1.43
|
|
4
|
MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.
|
PLoS One
|
2012
|
1.30
|
|
5
|
Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity.
|
Mol Cell Biol
|
2006
|
1.22
|
|
6
|
Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark.
|
Mol Cell Biol
|
2010
|
1.21
|
|
7
|
Deregulated E2F and the AAA+ coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer.
|
Mol Cancer Res
|
2010
|
1.05
|
|
8
|
Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression.
|
Cancer Lett
|
2007
|
1.05
|
|
9
|
Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
|
Mol Cell Biol
|
2012
|
1.02
|
|
10
|
Nuclear receptor coregulators as a new paradigm for therapeutic targeting.
|
Adv Drug Deliv Rev
|
2010
|
0.98
|
|
11
|
Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
|
Prostate
|
2012
|
0.85
|
|
12
|
Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
|
Prostate
|
2008
|
0.83
|
|
13
|
The roles and action mechanisms of p160/SRC coactivators and the ANCCA coregulator in cancer.
|
Prog Mol Biol Transl Sci
|
2009
|
0.78
|
|
14
|
Corrigendum: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.
|
Nat Med
|
2016
|
0.75
|